Zhongguo Zhongyao Zazhi最新文献

The study employed an evidence mapping approach to systematically review clinical research on TCM for diabetic kidney disease(DKD) over the past six years and evaluate the current state of evidence, aiming to provide a scientific basis and decision reference for current gaps and future research directions. A comprehensive literature search was conducted across databases including CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, EMbase, and Cochrane Library, yielding 310 publications related to TCM treatment of DKD. These included 289 randomized controlled trials(RCTs), 13 systematic reviews/Meta-analyses, and 8 guidelines/expert consensus documents. The analysis revealed an overall upward trend in publication volume, with oral administration being the predominant intervention method. Treatment durations were typically from two to three months, and sample sizes mostly ranged between 50-100 patients. A total of 30 different TCM decoctions and 39 Chinese patent medicines were investigated, with Shenqi Dihuang Decoction and Yishen Huashi Granules being the most frequently studied. The primary TCM syndrome patterns identified were Qi and Yin deficiency and spleen-kidney deficiency. Outcome indicators predominantly focused on clinical response rates, blood glucose-related indicators, and renal function parameters, with a notable lack of long-term outcome assessments. Methodological quality evaluation indicated significant shortcomings in RCT, particularly in allocation concealment and blinding, resulting in an overall low quality of evidence. Similarly, the systematic reviews/Meta-analyses were rated as "very low". In contrast, the guidelines and expert consensus documents demonstrated relatively acceptable quality, but there was room for further improvement in rigor and clinical application. The findings underscore the need for future research to address these methodological deficiencies, particularly by improving trial design and leveraging TCM advantages, so as to provide a more reliable evidence base for clinical decision-making in DKD prevention and treatment.

The International Organization for Standardization(ISO)/Technical Committee on Traditional Medicine(TC 249)/Subcommittee on Traditional Chinese Medicine(SC1), has long been dedicated to establishing a unified international standard system for traditional Chinese medicine(TCM), thereby promoting the high-quality development of the TCM industry through international standards. The development of ISO standards in the field of Chinese herbal medicine is among its core missions. Currently, the ISO standards for Chinese herbal medicine are playing a positive role in fostering the rapid development of its global trade and industry. However, the level of global promotion and application of ISO standards, particularly their integration and information sharing with the world's mainstream pharmacopoeias, remains in the initial exploratory stage. The primary reason for this is that the coordinated development model between ISO standards and the world's mainstream pharmacopoeias in terms of law, function, and technology is still unclear. To address this issue, this study constructed a three-dimensional comparison framework( "Law-Function-Technology"), systematically analyzed the root causes of standard disparities, and proposed a "trinity" collaborative strategy based on this analysis: from a legal perspective, bridge standard gaps through progressive integration; from a functional level, establish a dual-track quality control system that integrates ISO process management with pharmacopoeia terminal spot checks; from a technical perspective, create a collaborative mechanism for "safety-quality" classification indicators, aiming to promote technical sharing and coordinated development between ISO standards and mainstream pharmacopoeia standards.

This study aimed to assess the antitumor efficacy of a liposome hydrogel(GA-ICG-Lip-gel) co-loaded with gambogic acid(GA) and indocyanine green(ICG) both in vitro and in vivo, in combination with near infrared(NIR). The biological safety of GA-ICG-Lip-gel was assessed through the hemolysis assay. The inhibitory effects of various formulations, alone and in combination with 808 nm(2.5 W·cm~(-2)) NIR irradiation, on tumor cells were evaluated using the CCK-8 assay. A BALB/c mouse model with 4T1 breast cancer was established. In vivo photothermal properties of the nanocomposite system were assessed via infrared thermal imaging. The anticancer efficacy of GA-ICG-Lip-gel was evaluated through pharmacodynamic testing, hematoxylin-eosin(HE) staining, TdT-mediated dUTP Nick-end labeling(TUNEL) of tumor tissue, and Ki67 immunohistochemistry for proliferation cell-associated antigen. Interleukin-6(IL-6) levels were measured using an ELISA assay, along with tumor necrosis factor-α(TNF-α) and interferon-γ(IFN-γ) levels. RESULTS:: indicate that GA-ICG-Lip-gel exhibits excellent biological safety and photothermal stability, with a concentration-and time-dependent inhibitory effect on 4T1 cells. The cellular uptake of GA-ICG-Lip-gel by 4T1 cells is highly efficient, leading to a significant suppression of their migratory capacity. In vivo, GA-ICG-Lip-gel exhibits excellent photothermal conversion properties and effectively inhibits the growth of 4T1 breast cancer cells. ELISA assay results indicate that GA-ICG-Lip-gel + NIR notably increases the levels of IL-6, TNF-α, and IFN-γ in tumor-bearing mice. In summary, GA-ICG-Lip-gel serves as a promising nanodrug delivery platform that, when combined with NIR irradiation, displays potent antitumor effects both in vitro and in vivo.

This study aims to investigate whether Scutellariae Radix-Gardeniae Fructus(S-G) drug pairs alleviate joint inflammation and bone erosion in collagen-induced arthritis(CIA) mice by regulating sphingosine kinase 1(SphK1)-mediated glycolysis and inhibiting the differentiation of osteoclasts(OCs) induced by receptor activator of nuclear factor-κB ligand(RANKL). Potential therapeutic targets of S-G drug pairs were screened via network pharmacology, followed by Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment and molecular docking analyses. The effects of S-G drug pairs on bone erosion, inflammatory cytokines, glycolysis-related factors, and OCs differentiation were evaluated using both the CIA mouse model and the RAW264.7 cell in vitro induction system. In vivo results showed that S-G drug pairs alleviated joint swelling and synovial inflammation, reduced OCs number, and modulated the expression of key cytokines, including RANKL, osteoprotegerin(OPG), interleukin(IL)-6, and IL-10. In vitro findings further demonstrated that serum containing the drug significantly inhibited RANKL-induced OCs differentiation, reduced F-actin ring formation, and lowered levels of lactate acid(LA) and lactate dehydrogenase A(LDH-A). Additionally, it suppressed the expression of glycolysis-and bone resorption-related proteins and genes such as SphK1, pyruvate kinase M2(PKM2), oncoprotein c-Myc(c-Myc), and cathepsin K(CTSK), while also weakening the interaction between SphK1 and PKM2. In conclusion, S-G drug pairs could inhibit OCs differentiation by regulating SphK1-mediated glycolytic metabolism, thereby mitigating rheumatoid arthritis-induced bone erosion.

This study aimed to systematically evaluate the clinical efficacy and safety of Shiwei Longdanhua Granules/Capsules in the treatment of bronchitis, providing evidence-based support for clinical practice. Databases including CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, Cochrane Library, and Web of Science were searched for randomized controlled trials(RCTs) of Shiwei Longdanhua Granules/Capsules for bronchitis, from database inception to July 2025. Two investigators independently extracted data from the included studies, including sample size, patient characteristics, interventions, outcome measures, and adverse effects. Methodological quality was assessed using appropriate quality assessment tools, and Meta-analysis was performed using RevMan 5.4 software. A total of 16 RCTs involving 2 068 patients with bronchitis were included. Meta-analysis showed that, compared with antibiotics combined with expectorants and cough suppressants, Shiwei Longdanhua Granules improved the total efficiency(RR=1.33, 95%CI[1.17, 1.51]) and efficiency of relieving coughing(RR=1.23, 95%CI[1.11, 1.36]). Compared with antibiotics alone, Shiwei Longdanhua Granules improved the total efficiency(RR=1.25, 95%CI[1.16, 1.35]) and shortened the time to improvement of pulmonary rales(MD=-1.44, 95%CI[-1.82,-1.07]), fever(MD=-1.08, 95%CI[-1.18,-0.98]), and coughing(MD=-1.46, 95%CI[-1.84,-1.09]). Combined with antibiotics, Shiwei Longdanhua Granules/Capsules further reduced the time to cough relief(MD=-1.13, 95%CI[-1.54,-0.71]) and fever(MD=-1.14, 95%CI[-1.31,-0.97]). For acute bronchitis in children, Shiwei Longdanhua Granules/Capsules improved the total efficiency(RR=1.29, 95%CI[1.09, 1.52]) and efficiency of relieving coughing(RR=1.35, 95%CI[1.05, 1.75]) compared with antibiotics alone. These results suggest that Shiwei Longdanhua Granules/Capsules may have therapeutic effects for acute bronchitis, acute exacerbations of chronic bronchitis, and acute bronchitis in children. However, the number of clinical studies is limited, and their quality requires further improvement. Standardization of clinical trial procedures is needed to enhance evidence quality and provide stronger support for clinical application.

This study aimed to investigate the chemical constituent changes in Euphorbia fischeriana during milk-processing(a Mongolian medicine processing method) and elucidate its detoxification mechanism. Using UPLC-ZenoTOF-MS/MS technology, the chemical constituents of raw, milk-processed, and water-processed E. fischeriana were collected and analyzed. Principal component analysis(PCA) and orthogonal partial least squares-discriminant analysis(OPLS-DA) were applied to screen differential constituents. The quantitative analysis of five major differential constituents, including 17-hydroxyjolkinolide B(17-OH-JNB), jolkinolide B(JNB), 11β-hydroxy-8,14-epoxy-ent-abieta-13(15)-en-16, 12β-olide(11β-OH-abietolide), ent-3β-hydroxyatis-16-ene-14-one(3β-OH-atisene-14-one), and euphopilolide(EPD) was performed using UPLC-QTRAP-MS/MS with an external standard method. A total of 49 compounds were identified from raw, milk-processed, and water-processed E. fischeriana, including 47 diterpenoids(33 abietane-type, 9 atisane-type, and 5 tigliane-type), 1 acetophenone, and 1 polyphenol. Multivariate statistical analysis identified 17 differential constituents with VIP>1.0, P<0.05, FC<0.8 or >1.2 as conditions, all being diterpenoids. Quantitative results demonstrated decreased content(25.2%-65.3%) of the five differential constituents after milk-processing, with the most significant reduction observed for 17-OH-JNB(65.3%). In vitro cytotoxicity evaluation revealed that 17-OH-JNB, 11β-OH-abietolide, and 3β-OH-atisene-14-one exhibited potent growth inhibition against IEC-6 cells, and their IC_(50) is(1.26±0.07),(0.93±0.03), and(0.40±0.08) μmol·L~(-1), respectively. EPD showed weaker activity, with IC_(50) of(23.60±1.44) μmol·L~(-1), while JNB displayed no inhibitory effect at 100 μmol·L~(-1). The evaluation of intestinal organoid permeability demonstrated that both 17-OH-JNB and 3β-OH-atisene-14-one significantly increased permeability, with rates reaching 61.43% and 36.36%, respectively. As the primary toxic constituents with high abundance in raw and water-processed materials, the marked reduction of these diterpenoids after milk-processing may represent the key detoxification mechanism. This study provides scientific evidence for milk-processing mediated detoxification through qualitative and quantitative validation, enriches Mongolian medicine processing theory, and offers references for processing research of other toxic medicinal materials.

The aim of this study is to investigate whether saikosaponin B2(SSB2) promotes oligodendrocyte maturation and myelination by activating protein kinase B(Akt)/mammalian target of rapamycin(mTOR) pathway to improve the depression phenotype associated with vascular dementia(VaD). C57BL/6 mice were used as the research subjects. The VaD depression model was established by bilateral common carotid artery stenosis(BCAS) combined with chronic restraint stress(CRS). There were sham group, SSB2 group, BCAS/CRS group, and BCAS/CRS+SSB2 group. Depression-like behavior was assessed using the forced swim test and the tail suspension test. HE staining and TUNEL staining were used to observe the pathology and apoptosis of the corpus callosum. Immunofluorescence was used to detect the number of CC1~+ mature oligodendrocytes. Western blot was used to analyze the expression of myelin related proteins [myelin basic protein(MBP), myelin oligodendrocyte glycoprotein(MOG), myelin associated glycoprotein(MAG)], p-Akt, and p-mTOR. In vitro, primary oligodendrocyte precursor cells(OPCs) were treated with different concentrations of SSB2. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay was used to detect cell viability, and Western blot was used to detect the changes in the above proteins. The results showed that SSB2 significantly ameliorated BCAS/CRS-induced depression-like behavior and myelin structure damage in the corpus callosum of mice, increased the number of CC1~+ cells and the expression of myelin-related proteins, and activated the Akt/mTOR pathway. In vitro experiments further confirmed that SSB2 could increase the expression of MBP, MOG, MAG and the levels of p-Akt and p-mTOR in OPCs in a dose-dependent manner, and had no effect on cell viability. In conclusion, SSB2 may promote oligodendrocyte maturation and myelin repair by activating the Akt/mTOR signaling pathway, thus improving VaD related depressive behavior. This finding provides a new theoretical basis for the prevention and treatment of VaD comorbid depression.

Alcoholic liver injury is the pathological damage of the liver caused by long-term excessive drinking. With the development of traditional medicine, many TCMs have shown great advantages in the protection of alcoholic liver disease. As a kind of natural macromolecular substance, polysaccharides have biological activities such as inhibiting oxidative stress and regulating lipid metabolism and intestinal flora. Recent studies have shown that a variety of polysaccharides in TCM have protective effects on alcoholic liver disease. This study extensively consulted the Chinese and foreign literature on the research progress of polysaccharides in TCM for the treatment of alcoholic liver disease in recent five years in the databases of CNKI, Web of Science, PubMed, and so on, screened and summarized the relevant mechanisms and research progress, and made prospects, so as to provide a reference for the clinical prevention and treatment of alcoholic liver disease.